Nexus Dx is a San Diego-based company specializing in in vitro diagnostic (IVD) products. Their flagship technology, the Nexus IB10, offers a range of sphingotest assays for various biomarkers, including Troponin-99, NT-proBNP, D-Dimer, TSH, beta-hCG, SOB, PCT, and penKid, with a 3-in-1 Cardiac option also available. However, it should be noted that these IVD products are not currently approved for use or distribution in the United States or Canada.
With a focus on personalized medicine, Nexus Dx is at the forefront of biomarker-guided trials, such as the one led by University Hospital Hamburg-Eppendorf UKE, which explores new avenues for COVID-19 treatment. Additionally, their Proenkephalin penKid assay addresses diagnostic blind spots in assessing acute kidney injury in children. Committed to quality and innovation, Nexus Dx continues to make strides in the field of IVD technology.
Generated from the website